Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 78% Improvement Relative Risk Case (b) 80% Hellwig et al. Ivermectin for COVID-19 Prophylaxis Does ivermectin reduce COVID-19 infections? Ecological study in multiple countries Fewer cases with ivermectin (p=0.017) Hellwig et al., Int. J. Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248 Favors ivermectin Favors control
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248
Hellwig et al., A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248
Nov 2020   Source   PDF  
  All Studies   Meta
Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases. This study is excluded in the after exclusion results of meta analysis: not a typical trial, analysis of African countries that used or did not use ivermectin prophylaxis for parasitic infections.
risk of case, 78.0% lower, RR 0.22, p < 0.02, African countries, PCTI vs. no PCT, relative cases per capita.
risk of case, 80.0% lower, RR 0.20, p < 0.001, worldwide, PCTI vs. no PCT, relative cases per capita.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hellwig et al., 28 Nov 2020, retrospective, ecological study, multiple countries, peer-reviewed, 2 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. International Journal of Antimicrobial Agents 57 (2021) 106248 Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin Martin D. Hellwig a,∗, Anabela Maia b a b Plymouth State University, 17 High Street, Plymouth, NH, USA Rhode Island College, 600 Mount Pleasant Avenue, Providence, RI, USA a r t i c l e i n f o Article history: Received 20 June 2020 Accepted 22 November 2020 Keywords: SARS-CoV-2 COVID-19 Prophylaxis Ivermectin Mass drug administration Prophylactic chemotherapy a b s t r a c t As COVID-19 (coronavirus disease 2019) continues to rapidly spread throughout the world, the incidence varies greatly among different countries. These differences raise the question whether nations with a lower incidence share any medical commonalities that could be used not only to explain that lower incidence but also to provide guidance for potential treatments elsewhere. Such a treatment would be particularly valuable if it could be used as a prophylactic against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission, thereby effectively slowing the spread of the disease while we await the wide availability of safe and effective vaccines. Here, we show that countries with routine mass drug administration of prophylactic chemotherapy including ivermectin have a significantly lower incidence of COVID-19. Prophylactic use of ivermectin against parasitic infections is most common in Africa and we hence show that the reported correlation is highly significant both when compared among African nations as well as in a worldwide context. We surmise that this may be connected to ivermectin’s ability to inhibit SARS-CoV-2 replication, which likely leads to lower infection rates. However, other pathways must exist to explain the persistence of such an inhibitory effect after serum levels of ivermectin have declined. It is suggested that ivermectin be evaluated for potential off-label prophylactic use in certain cases to help bridge the time until a safe and effective vaccine becomes available. © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop